Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
Status:
Closed
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
NCT#03199885
BR004 is permanently closed to accrual, effective May 20, 2022.
